Personality measures in former heroin users receiving methadone or in protracted abstinence from opiates

Acta Psychiatrica Scandinavica

Volumn 112, Issue 2, 2005, Pages 149-158

  Cohen, Lisa J ^a,c   Gertmenian King, E ^a   Kunik, L ^a   Weaver, C ^a   London, E D ^b   Galynker, I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Addiction; Heroin; Methadone; Opiates; Personality; Personality disorders; Substance abuse

Indexed keywords

DIAMORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; DELUSIONAL DISORDER; DETOXIFICATION; DRUG WITHDRAWAL; FEMALE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILLON CLINICAL MULTIAXIAL INVENTORY II; PERSONALITY; PERSONALITY DISORDER; PERSONALITY TEST; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SUBSTANCE ABUSE; TEMPERAMENT AND CHARACTER INVENTORY; TREATMENT OUTCOME;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; BEHAVIOR; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; OPIOID-RELATED DISORDERS; PERSONALITY DISORDERS; PERSONALITY INVENTORY; REFERENCE VALUES; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 22344441307     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2005.00546.x     Document Type: Article

References (46)

1. BALL JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991.
2. CONDELLI WS, DUNTEMAN GH. Exposure to methadone programs and heroin use. Am J Drug Alcohol Abuse 1993; 19:65-78.
3. DEPT OF HEALTH & HUMAN SERVICES, SUBSTANCE ABUSE AND MENTAL HEALTH SERV. ADMIN. Opioid drugs in maintenance and detoxification treatment of opiate addiction: final rule. Fed Regist 2001;66:4075-4102.
4. GOSSOP M, MARSDEN J, STEWART D, TREACY S. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow up results from the national treatment outcome research study. Drug Alcohol Abuse 2001;62:255-264.
5. GOSSOP M, MARSDEN J, STEWART D, ROLFE A. Patterns of improvement after methadone treatment: 1 year follow-up results from the national treatment outcome research study (NTORS). Drug Alcohol Depend 2000;60:275-286.
6. MAXWELL JC, PULLUM TW, TANNERT K. Deaths of clients in methadone treatment in Texas: 1994-2002. Drug Alcohol Depend 2005;78:73-81.
7. BEST D, GOSSOP M, MAN LH, FINCH E, GREENWOOD J, STRANG J. Accidental and deliberate overdose among opiate addicts in methadone maintenance treatment: are deliberate overdoses systematically different? Drug Alcohol Abuse 2000; 19:213-216.
8. VERDEJO A, TORIBIO I, OROZCO C, PUENTE KL, PEREZ-GARC'A M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 2005 (in press).
9. GREENFIELD L, FOUNTAIN D. Influence of time in treatment and follow-up duration on methadone treatment outcomes. J Psychopathol Behav Assess 2000;22:353-364.
10. LAHEIJ RJF, KRABBE PFM, DE JONG CAJ. Rapid heroin detoxification under general anesthesia. JAMA 2000;283: 1143.
11. CALSYN DA, SAXON AJ. Personality disorder subtypes among cocaine and opioid addicts using the Millon Clinical Multiaxial Inventory. Int J Addict 1990;25:1037-1049.
12. MILLON T. Manual for the MCMI-II. Minneapolis, MN: National Computer Systems, 1987.
13. CRAIG RJ. Prevalence of personality disorders among cocaine and heroin addicts. Substance Abuse 2000;21:87-94.
14. MARSH DT, STILE SA, STOUGHTON NL, TROUT-LANDEN BL. Psychopathology of opiate addiction: comparative data from the MMPI and MCMI. Am J Drug Alcohol Abuse 1988;14:17-27.
15. BALL SA, CECERO JJ. Addicted patients with personality disorders: traits, schemas, and presenting problems. J Personal Disord 2001;15:72-83.
16. FIRST MB, GIBBON M, SPITZER RL, WILLIAMS JDW. User's guide for the structured clinical interview for DSM-IV axis II personality disorders. Washington, DC: American Psychiatric Press, 1995.
17. CLONINGER RC. A psychobiological model of temperament and character. Arch Gen Psychiatry 1993;50:975-990.
18. GUITERREZ F, SNGORRIN J, MARTIN-SANTOS R, TORRES X, TORRENS M. Measuring the core features of personality disorders in substance abusers using the Temperament and Character Inventory (TCI). J Personal Disord 2002;16: 344-359.
19. BALL SA, ROUNSAVILLE BJ, TENNEN H, KRANZLER HR, POLING JC. Personality, temperament, and character dimensions and DSM-IV personality disorders in substance abusers. J Abnormal Psychol 1997;106:545-553.
20. CACCIOLA JS, ALTERMAN AI, RUTHERFORD MJ, MCKAY JR, MULVANEY FD. The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001;61:271-280.
21. KING VL, KIDORF MS, STOLLER K, CARTER JA., BROONER RK. Influence of antisocial personality subtypes on drug abuse treatment response. J Nerv Ment Dis 2001;189:593-601.
22. CALSYN DA, WELLS EA, FLEMING C, SAXON AJ. Changes in the MCMI scores among opiate addicts as a function of retention in methadone maintenance treatment and recent drug use. Am J Drug Alcohol Abuse 2000;26:297-309.
23. FIRST M, SPITZER R, GIBBON M, WILLIAMS J. Structured clinical interview for axis I DSM-IV disorders - patient edition Ver. 2. New York: Biometrics Research Department, New York State Psychiatric Institute, 1995.
24. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
25. SOBELL MB, MAISTO SA, SOBELL LC, COOPER AM, SANDERS S. Developing a prototype for evaluating alcohol treatment effectiveness. In: SOBELL LC, WARD E, eds. Evaluating alcohol and drug abuse treatment effectiveness: recent advances. New York: Pergamon, 1980:129-150.
26. KIRBY KN, PETRY NM, BICKEL WK. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 1999;128: 78-87.
27. TREMEAU F, DARREYE A, LEROY B et al. Personality changes in opioid-dependent subjects in a methadone maintenance treatment program. Encephale 2003;29:285-292.
28. SIEVER L, DAVIS K. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004;161:398-413.
29. KETY, SS. Mental illness in the biological and adoptive relatives of schizophrenic adoptees: findings relevant to genetic and environmental factors in etiology. Am J Psychiatry 1983;140:720-727.
30. KESHAVAN MS, DUGGAL HS, VEERAGANDHAM G et al. Personality dimensions in first-episode psychoses. Am J Psychiatry 2005;162:102-109.
31. MUNKNER R, HAASTRUP S, JORGENSEN T, ANDREASEN AH, KRAMP P. Taking cognizance of mental illness in schizophrenics and its association with crime and substance-related diagnoses. Acta Psychiatr Scand 2003;107:111-117.
32. CRAIG RJ, VERNIS JS, WEXLER S. Personality characteristics of drug addicts and alcoholics on the Millon Clinical Multiaxial Inventory. J Pers Assess 1985;49:156-160.
33. CALSYN DA, ROSZELL DK, CHANEY EF. Validation of MMPI profile subtypes among opioid addicts who are beginning methadone maintenance treatment. J Clin Psychol 1989; 45:991-998.
34. TREECE C, NICHOLSON B. DSM-III personality type and dose levels in methadone maintenance patients. J Nerv Ment Dis 1980;168:621-628.
35. SIEVER LJ, AMIN F, COCCARO EF et al. Plasma homovalinic acid in schizotypal personality disorder. Am J Psychiatry 1993;150:149-151.
36. SCHMAUSS C, EMRICH HM. Dopamine and the action of opiates: a reevaluation of dopamine hypothesis of schizophrenia with special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry 1985;20:1211-1231.
37. SCHMAUSS C, YASSOURDIS A, EMRICH HM. Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry 1987;144:1340-1342.
38. BRIZER DA, HARTMAN N, SWEENEY J, MILLMAN RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 1985;142: 1106-1107.
39. LEVINSON I, GALYNKER II, ROSENTHAL RN. Methadone withdrawal psychosis. J Clin Psychiatry 1995;56:73-76.
40. FISHBAIN DA, GOLDBERG M, ROSOMOFF RS, ROSOMOFF R. Atypical withdrawal syndrome (organic delusional syndrome) secondary to oxycodone detoxification [letter]. J Clin Psychopharmacol 1988;8:441-442.
41. SATEL SL, KOSTEN TR, SCHUKIT MA, FISCHMAN MW. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry 1993;150:695-704.
42. LATOWSKY M. Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. J Psychoactive Drugs 1996;28:251-257.
43. SPIELWOY C, MARKOU A. Withdrawal from chronic phenylclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology 2003;28: 1106-1116.
44. WATANABE KI, OGIHARA-HASHIZUME A, KOBAYASHI Y, MITSUSHIO H, KOMIYAMA T. Impaired sleep during the post-alcohol withdrawal period in alcoholic patients. Addict Biol 2001;6:163-169.
45. GOLDSTEIN A. Heroin addiction: neurobiology, pharmacology, and policy. J Psychoactive Drugs 1991;23:122-123.
46. KOENIGSBERG HW, REYNOLDS D, GOODMAN M et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003;64:628-634.